Home  /  Resource Library  /  Impact of rituximab and half-dose CHOP as primary therapy for untreated symptomatic Waldenstrom Macroglobulinemia: review of a combined regimen of rituximab with an alkylating agent

Impact of rituximab and half-dose CHOP as primary therapy for untreated symptomatic Waldenstrom Macroglobulinemia: review of a combined regimen of rituximab with an alkylating agent

This retrospective study investigated the outcomes of patients with Waldenstrom Macroglobulinemia who received rituximab and half-dose CHOP regimen.